Intellia Therapeutics (NTLA) Stock Price, Quote, News & History | Benzinga

Comments

Intellia Therapeutics Inc (NTLA) Stock Price, Quote, News & History

NTLANASDAQ

Trade with Public

Trade with Public

$11.87

0.252.15%

At close: Feb 13, 4:00 PM EST

$11.89

0.020.17%

After Hours: Feb 13, 7:50 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

$11.54

Close

$11.87

Volume / Avg.

2.63M / 5.04M

Day Range

$11.54 - $12.32

52 Wk Range

5.90 - 28.25

Market Cap

$1.38B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

43.89%

Days to Cover

5.69

Recent Intellia Therapeutics Inc News

Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder

FDA removes the clinical hold on Intellia's Phase 3 trial for a rare nerve disease after safety updates, while review continues for its heart disease program.

Vandana Singh

HCA Healthcare Posts Upbeat Q4 Earnings, Joins Redwire, General Motors And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.

Erica Kollmann

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-410.65M

Investing Cash Flow (TTM)

352.06M

Financing Cash Flow (TTM)

131.83M

Free Cash Flow (TTM)

-412.63M

Capital Expenditure (TTM)

-1.98M

Net Change in Cash (TTM)

73.24M

Analyst Trends and Forecast

1

1

Sep 25

5

2

Oct 25

4

2

1

Nov 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.01B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

21.18

PB Ratio (TTM)

1.80

Earnings Yield % (TTM)

-36.57%

Earnings Yield % (FWD)

-31.50%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$6.46

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$193.39M

Debt to Equity

0.13

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$11.54

Close

$11.87

Volume / Avg.

2.63M / 5.04M

Day Range

$11.54 - $12.32

52 Wk Range

5.90 - 28.25

Market Cap

$1.38B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

43.89%

Days to Cover

5.69

About

Sector

Health Care

Industry

Biotechnology

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Intellia Therapeutics (NTLA) stock?

A

You can purchase shares of Intellia Therapeutics (NASDAQ:NTLA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Intellia Therapeutics (NTLA) competitors?

A

Other companies in Intellia Therapeutics’s space includes: MoonLake Immunotherapeutics (NASDAQ:MLTX), Immatics NV (NASDAQ:IMTX), Day One Biopharmaceuticals Inc (NASDAQ:DAWN), Pharming Group (NASDAQ:PHAR) and AnaptysBio Inc (NASDAQ:ANAB).

Q

What is the forecast, or price target, for Intellia Therapeutics (NTLA) stock?

A

Intellia Therapeutics has a consensus price target of $27.52.

Q

What is the current price for Intellia Therapeutics (NTLA)?

A

The stock price for Intellia Therapeutics (NASDAQ: NTLA) is $11.89 last updated February 13, 2026 at 7:50 PM EST.

Q

Does Intellia Therapeutics (NTLA) pay a dividend?

A

There are no upcoming dividends for Intellia Therapeutics.

Q

When is Intellia Therapeutics (NASDAQ:NTLA) reporting earnings?

A

Intellia Therapeutics does not have any upcoming earnings scheduled.

Q

Is Intellia Therapeutics (NTLA) going to split?

A

There is no upcoming split for Intellia Therapeutics.

Q

What sector and industry does Intellia Therapeutics (NTLA) operate in?

A

Intellia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

MoonLake Immunotherapeutics

Day One Biopharmaceuticals Inc

Tyra Biosciences Inc

Relay Therapeutics Inc

Monte Rosa Therapeutics Inc